AeroGrow International 10-Q10 Nov 142015 Q2 Quarterly reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
Document And Entity Information	Sep. 30, 2014	Nov. 05, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'AeroGrow International, Inc.	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--03-31	'
Entity Common Stock, Shares Outstanding	'	6,536,018
Amendment Flag	'false	'
Entity Central Index Key	'0001316644	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2015	'
Document Fiscal Period Focus	'Q2	'

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
Current assets	'	'
Cash	$1,140	$1,707
Restricted cash	15	15
Accounts receivable, net of allowance for doubtful accounts of $9 and $5 at September 30, 2014 and March 31, 2014, respectively	911	573
Other receivables	81	187
Inventory	5,017	1,311
Prepaid expenses and other	789	306
Total current assets	7,953	4,099
Property and equipment, net of accumulated depreciation of $3,129 and $3,024 at September 30, 2014 and March 31, 2014, respectively	555	298
Other assets	'	'
Intangible assets	2	2
Deposits	156	145
Total other assets	158	147
Total assets	8,666	4,544
Current liabilities	'	'
Accounts payable	2,702	553
Accrued expenses	436	306
Deferred rent	0	3
Notes payable	2,537	0
Derivative warrant liability	2,742	2,530
Debt associated with sale of intellectual property	232	258
Total current liabilities	8,649	3,650
Commitments and contingencies	'	'
Stockholders' equity	'	'
Preferred stock, $.001 par value, 20,000,000 shares authorized, 2,649,007 issued and outstanding at September 30, 2014 and March 31, 2014	3	3
Common stock, $.001 par value, 750,000,000 shares authorized, 6,536,018 and 6,129,326 shares issued and outstanding at September 30, 2014 and March 31, 2014, respectively	7	6
Additional paid-in capital	81,145	79,563
Stock dividend to be distributed	446	1,456
Accumulated deficit	-81,584	-80,134
Total stockholders' equity	17	894
Total liabilities and stockholders' equity	$8,666	$4,544

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parentheticals) (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
Allowance for doubtful accounts (in Dollars)	$9	$5
Accumulated depreciation (in Dollars)	$3,129	$3,024
Preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	2,649,007	2,649,007
Preferred stock, shares outstanding	2,649,007	2,649,007
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	6,536,018	6,129,326
Common stock, shares outstanding	6,536,018	6,129,326

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net revenue	$1,707	$676	$3,390	$1,799
Cost of revenue	1,083	388	2,227	1,110
Gross profit	624	288	1,163	689
Operating expenses	'	'	'	'
Research and development	115	85	198	146
Sales and marketing	484	325	1,026	748
General and administrative	506	399	1,056	806
Total operating expenses	1,105	809	2,280	1,700
(Loss) from operations	-481	-521	-1,117	-1,011
Other (expense) income, net	'	'	'	'
Fair value changes in derivative warrant liability	11	-12	-212	-12
Interest expense	0	-21	0	-52
Interest expense b related party	-37	-3	-37	-6
Other income	0	16	2	533
Total other (expense) income, net	-26	-20	-247	463
Net (loss)	-507	-541	-1,364	-548
Less: Deemed dividend on convertible preferred stock	0	0	0	-268
Change in fair value of preferred stock dividend	154	-81	-86	-141
Net income (loss) attributable to common shareholders	($353)	($622)	($1,450)	($957)
Net loss per share, basic and diluted (in Dollars per share)	($0.06)	($0.11)	($0.23)	($0.12)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	6,405	5,905	6,268	5,905

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net (loss)	($1,364)	($548)
Adjustments to reconcile net (loss) to cash used by operations:	'	'
Issuance of common stock and options under equity compensation plans	136	87
Issuance of common stock warrants	37	0
Depreciation and amortization expense	105	71
Bad debt (recovery) expense	-1	2
Fair value remeasurement of derivative warrant liability	212	12
Accretion of debt associated with sale of intellectual property	-26	-22
Gain on the forgiveness of debt	0	-489
Amortization of debt issuance costs	0	13
SMG intellectual property royalty and branding license	135	47
Change in operating assets and liabilities:	'	'
(Increase) decrease in accounts receivable	-338	93
Decrease in other receivable	106	111
(Increase) in inventory	-3,705	-112
(Increase) in prepaid expense and other	-482	-296
(Increase) in deposits	-11	0
Increase in accounts payable	2,302	-35
Increase (decrease) in accrued expenses	130	-106
Increase in accrued interest	0	39
Increase in accrued interest-related party	37	7
(Decrease) in customer deposits	0	-70
(Decrease) in deferred rent	-3	0
Net cash used by operating activities	-2,730	-1,196
Cash flows from investing activities:	'	'
Decrease in restricted cash	0	17
Purchases of equipment	-362	-138
Proceeds from the sale of intellectual property	0	500
Net cash (used) provided by investing activities	-362	379
Cash flows from financing activities:	'	'
Proceeds from notes payable, net	2,500	0
Repayments of notes payable	0	-246
Repayments of notes payable b related party	0	-54
Repayments of long term debt borrowings	0	-1,160
Proceeds from the exercise of stock options	25	0
Proceeds from the issuance of preferred stock	0	4,000
Payments for offering costs of preferred stock	0	-157
Net cash provided by financing activities	2,525	2,383
Net (decrease) increase in cash	-567	1,566
Cash, beginning of period	1,707	525
Cash, end of period	1,140	2,091
Cash paid during the year for:	'	'
Interest	0	37
Income taxes	0	0
Supplemental disclosure of non-cash investing and financing activities:	'	'
Deemed dividend on convertible preferred stock	0	268
Decrease of inventory associated with debt settlement	0	237
Fair value of derivative warrant liability	0	564
Fair value of warrant issued to placement agent	0	108
Debt associated with sale of intellectual property	0	297
Change in fair value of stock dividends accrued on convertible preferred stock	86	141
Decrease in liability due to issuance of SMG shares	$288	$0

1_Description_of_Business

1. Description of Business	6 Months Ended
1. Description of Business	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Business Description and Basis of Presentation [Text Block]	'
	1. Description of Business

	AeroGrow International, Inc. (the “Company," “AeroGrow,” “we,” “our,” or “us”) was formed as a Nevada corporation on March 25, 2002. The Company’s principal business is developing, marketing, and distributing advanced indoor aeroponic garden systems designed and priced to appeal to the consumer gardening, cooking and small indoor appliance markets worldwide. The Company manufactures, distributes and markets seven different models of its AeroGarden systems in multiple colors, as well as over 40 varieties of seed pod kits and a full line of accessory products through multiple channels including retail, catalogue and direct-to-consumer sales primarily in the United States and Canada, as well as selected countries in Europe, Asia and Australia.

2_Liquidity_and_Basis_of_Prese

2. Liquidity and Basis of Presentation	6 Months Ended
	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Basis of Presentation and Significant Accounting Policies [Text Block]	'
	2. Liquidity and Basis of Presentation

	Interim Financial Information

	The unaudited interim financial statements of the Company included herein have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim reporting including the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These condensed statements do not include all disclosures required by accounting principles generally accepted in the United States of America (“U.S. GAAP”) for annual audited financial statements and should be read in conjunction with the Company’s audited financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2014, as filed with the SEC on June 30, 2014.

	In the opinion of management, the accompanying unaudited interim financial statements reflect all adjustments, including normal recurring adjustments, necessary to present fairly the financial position of the Company at September 30, 2014, the results of operations for the three and six months ended September 30, 2014 and 2013, and the cash flows for the six months ended September 30, 2014 and 2013. The results of operations for the three and six months ended September 30, 2014 are not necessarily indicative of the expected results of operations for the full year or any future period. In this regard, the Company’s business is highly seasonal, with approximately 60.9% of revenues in the fiscal year ended March 31, 2014 (“Fiscal 2014”) occurring in the four consecutive calendar months of October through January. Furthermore, during the six-month period ended September 30, 2014, the Company has continued to expand its distribution channel in anticipation of the peak sales season. The balance sheet as of March 31, 2014 is derived from the Company’s audited financial statements.

	Sources of funding to meet prospective cash requirements include the Company’s existing cash balances, cash flow from operations, and borrowings under the Company’s debt arrangements.

	On July 10, 2014, the Company entered into a Term Loan Agreement in the principal amount of up to $4.5 million with a wholly owned subsidiary of The Scotts Miracle-Gro Company (collectively with its subsidiary, “SMG” or “Scotts Miracle-Gro”). The proceeds were made available as needed in three advances of up to $1.0 million, $1.5 million, and $2.0 million in July, August, and after September of 2014, respectively, with a due date of February 15, 2015. The Term Loan Agreement is secured by a lien on the assets of the Company. Interest is charged at the stated rate of 10% per annum, but will paid in shares of AeroGrow common stock, valued at a price per share equal to the conversion price of the Series B Convertible Preferred Stock (the “Series B Preferred Stock”), (which was previously issued to Scotts Miracle-Gro in April 2013, as disclosed in Note 4 below) up to 30 days after the date the Term Loan is paid in full. The funding provided general working capital and was used for the purpose of acquiring inventory to support anticipated growth as the Company expands its retail and its direct-to-consumer sales channels. The first advance of $1.0 million was borrowed in July 2014 followed by an additional $1.5 million in August 2014. See Note 3 “Notes Payable, Long Term Debt and Current Portion – Long Term Debt” to our condensed financial statements.

	Significant Accounting Policies

	Use of Estimates

	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. It is reasonably possible that a change in the Company’s estimates could occur in the near term as information becomes available.

	Net Income (Loss) per Share of Common Stock

	The Company computes net income (loss) per share of common stock in accordance with Accounting Standards Codification (“ASC”) 260. ASC 260 requires companies with complex capital structures to present basic and diluted earnings per share (“EPS”). Basic EPS is measured as the income or loss available to common stockholders divided by the weighted average shares of common stock outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common stock (e.g., convertible securities, options, and warrants) as if it had been converted at the beginning of the periods presented. Potential shares of common stock that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. All potentially dilutive securities outstanding have been excluded for the periods presented since their effect would be antidilutive.

	Reclassifications

	Certain prior year amounts have been reclassified to conform to current year presentation.

	Concentrations of Risk

	ASC 825-10-50-20 requires disclosure of significant concentrations of credit risk regardless of the degree of such risk. Financial instruments with significant credit risk include cash deposits. The amount on deposit with one financial institution exceeded the $250,000 federally insured limit as of September 30, 2014. However, management believes that the financial institution is financially sound and the risk of loss is minimal.

	Customers:

	For the three months ended September 30, 2014, the Company had two customers, BJ’s Wholesale Club and Amazon.com, that represented 30.4% and 18.4% of net revenue, respectively. For the three months ended September 30, 2013, the Company had two customers, Amazon.com and Canadian Tire Company, that represented 27.0% and 11.6% of the Company’s net revenue, respectively. For the six months ended September 30, 2014, the Company had two customers, Amazon.com and BJ’s Wholesale Club, that represented 16.4% and 15.3% of the Company’s net revenue, respectively. For the six months ended September 30, 2013, the Company had one customer, Amazon.com, that represented 18.0% of the Company’s net revenue.

	Suppliers:

	For the three months ended September 30, 2014, the Company purchased inventories and other inventory-related items from six suppliers totaling $2.4 million, $982,000, $549,000, $373,000, $147,000 and $116,000, representing 218.7%, 90.6%, 50.7%, 34.4%, 13.6% and 10.7% of cost of revenue, respectively, as we ramp up inventory levels for the holiday season. For the three months ended September 30, 2013, the Company purchased inventories and other inventory-related items from four suppliers totaling $489,000, $194,000, $65,000 and $44,000, representing 125.8%, 50.0%, 16.7% and 11.3% of cost of revenue, respectively. For the six months ended September 30, 2014, the Company purchased inventories and other inventory-related items from five suppliers totaling $2.8 million, $1.0 million, $549,000, $390,000 and $322,000, representing 127.1%, 47.1%, 24.7%, 17.5% and 14.5% of cost of revenue, respectively. For the six months ended September 30, 2013, the Company purchased inventories and other inventory-related items from four suppliers totaling $530,000, $285,000, $93,000 and $65,000, representing 47.8%, 25.7%, 8.3% and 5.9% of cost of revenue, respectively.

	The Company’s primary contract manufacturers are located in China. As a result, the Company may be subject to political, currency, regulatory, transportation, third-party labor and weather/natural disaster risks. Although the Company believes alternate sources of manufacturing could be obtained, these risks could have an adverse impact on our operations.

	Accounts Receivable:

	As of September 30, 2014, the Company had two customers, BJ’s Wholesale club and Amazon.com, that represented 56.9% and 22.7% of the Company’s outstanding accounts receivable. As of March 31, 2014, the Company had three customers, Amazon.com, Costco.com and The Home Depot, that represented 44.1%, 24.5% and 11.1%, respectively, of outstanding accounts receivable. The Company believes that all receivables from these customers are collectible.

	Fair Value of Financial Instruments

	The Company follows the guidance in ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), as it relates to the fair value of its financial assets and liabilities. ASC 820 provides for a standard definition of fair value to be used in new and existing pronouncements. This guidance requires disclosure of fair value information about certain financial instruments (insurance contracts, real estate, goodwill and taxes are excluded) for which it is practicable to estimate such values, whether or not these instruments are included in the balance sheet at fair value. The fair values presented for certain financial instruments are estimates which, in many cases, may differ significantly from the amounts that could be realized upon immediate liquidation.

	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability, i.e., exit price, in an orderly transaction between market participants. ASC 820 also provides a hierarchy for determining fair value, which emphasizes the use of observable market data whenever available. The three broad levels defined by the hierarchy are as follows, with the highest priority given to Level 1 as this data is the most reliable, and the lowest priority given to Level 3.

	Level 1 – Quoted prices in active markets for identical assets.

	Level 2 – Quoted prices for similar assets in active markets, quoted prices for identical or similar assets in markets that are not active, or other inputs that are observable or can be corroborated by observable market data, including model-derived valuations.

	Level 3 – Unobservable inputs that are supported by little or no market activity.

	The carrying value of financial instruments including receivables, accounts payable and accrued expenses, approximates their fair value at September 30, 2014 and March 31, 2014 due to the relatively short-term nature of these instruments. As of September 30, 2014 and March 31, 2014, the fair value of the Company's debt, notes payable, and sale of intellectual property liability using Level 3 inputs was estimated using the discounted cash flow method, which is based on the future expected cash flows, discounted to their present values, using a discount rate of 15%.

	In conjunction with the Securities Purchase Agreement and strategic alliance Scotts Miracle-Gro, the Company issued a warrant that entitles, but does not obligate, Scotts Miracle-Gro to purchase a number of shares of common stock that, on a fully diluted basis, constitute 80% of the Company’s outstanding capital stock. This warrant was accounted for as a liability at its estimated fair value. The Company calculated the fair value of the warrant during the quarter ended September 30, 2014 using a Monte Carlo simulation model.

			30-Sep-14				31-Mar-14
			(in thousands)				(in thousands)
			Fair Value		Carry Value		Fair Value		Carry Value
Liabilities
Notes payable		$	2,469	$	2,537	$	-	$	-
Derivative warrant liability			2,742		2,742		2,530		2,530
Sale of intellectual property liability			158		232		171		258
Total		$	5,369	$	5,511	$	2,701	$	2,788

As of September 30, 2014, the Company measured the warrant at fair value and will continue to do so on a recurring basis subsequent to initial recognition. As of March 31, 2014, the Company did not have any financial assets or other liabilities that were measured at fair value on a recurring basis subsequent to initial recognition.

Accounts Receivable and Allowance for Doubtful Accounts

The Company sells its products to retailers and consumers. Consumer transactions are primarily paid by credit card. Retailer sales terms vary by customer, but generally range from net 30 days to net 60 days. Accounts receivable are reported at net realizable value and net of the allowance for doubtful accounts. The Company uses the allowance method to account for uncollectible accounts receivable. The Company's allowance estimate is based on a review of the current status of trade accounts receivable, which resulted in an allowance of $9,000 and $5,000 at September 30, 2014 and March 31, 2014, respectively.

Other Receivables

In conjunction with the Company’s processing of credit card transactions for its direct-to-consumer sales activities and as security with respect to the Company’s performance for credit card refunds and charge backs, the Company is required to maintain a cash reserve with Litle and Company, the Company’s credit card processor. This reserve is equal to 5% of the credit card sales processed during the previous six months. As of September 30, 2014 and March 31, 2014, the balance in this reserve account was $81,000 and $187,000, respectively.

Advertising and Production Costs

The Company expenses all production costs related to advertising, including print, television, and radio advertisements when the advertisement has been broadcast or otherwise distributed. The Company records media costs related to its direct-to-consumer advertisements, inclusive of postage and printing costs incurred in conjunction with mailings of direct- to-consumer catalogues, and related direct- to-consumer advertising costs, in accordance with ASC 340-20-25-Reporting on Advertising Costs. As prescribed by ASC 340-20-25, direct- to-consumer advertising costs incurred are reported as assets and are amortized over the estimated period of the benefits, based on the proportion of current period revenue from the advertisement to probable future revenue.

Advertising expense for the three and six months ended September 30, 2014 and 2013 were as follows:

		Three Months Ended				Six Months Ended
		September 30,				September 30,
		(in thousands)				(in thousands)
		2014		2013		2014		2013
Direct-to-consumer		$	63	$	40	$	168	$	112
Retail			5		2		13		2
Other			-		1		18		4
Total advertising expense		$	68	$	43	$	199	$	118

As of September 30, 2014 and March 31, 2014, the Company deferred $8,000 and $16,000, respectively, related to such media and advertising costs.

Inventory

Inventories are valued at the lower of cost, determined by the first-in, first-out method, or market. Included in inventory costs where the Company is the manufacturer are raw materials, labor, and manufacturing overhead. The Company records the raw materials at delivered cost. Standard labor and manufacturing overhead costs are applied to the finished goods based on normal production capacity as prescribed under ASC 330 Inventory Pricing. A majority of the Company’s products are manufactured overseas and are recorded at landed cost which includes product costs for purchased and manufactured products, and freight and transportation costs for inbound freight from manufacturers.

		September 30,		March 31,
		2014		2014
		(in thousands)		(in thousands)
Finished goods		$	3,954	$	784
Raw materials			1,063		527
		$	5,017	$	1,311

The Company determines an inventory obsolescence reserve based on management’s historical experience and establishes reserves against inventory according to the age of the product. As of September 30, 2014 and March 31, 2014, the Company had reserved $332,000 for inventory obsolescence.

Revenue Recognition

The Company recognizes revenue from product sales, net of estimated returns, when persuasive evidence of a sale exists, including the following; (i) a product is shipped under an agreement with a customer; (ii) the risk of loss and title has passed to the customer; (iii) the fee is fixed or determinable; and (iv) collection of the resulting receivable is reasonably assured.

The Company records estimated reductions to revenue for customer and distributor programs and incentive offerings, including promotions, rebates, and other volume-based incentives. Certain incentive programs require the Company to estimate based on industry experience the number of customers who will actually redeem the incentive. As of September 30, 2014 and March 31, 2014, the Company had accrued $39,000 and $42,000, respectively, as its estimate for the foregoing deductions and allowances.

Warranty and Return Reserves

The Company records warranty liabilities at the time of sale for the estimated costs that may be incurred under its basic warranty program. The specific warranty terms and conditions vary depending upon the product sold but generally include technical support, repair parts, and labor for periods up to one year. Factors that affect the Company’s warranty liability include the number of installed units currently under warranty, historical and anticipated rates of warranty claims on those units, and cost per claim to satisfy the Company’s warranty obligation. Based upon the foregoing, the Company has recorded a provision for potential future warranty costs of $17,000 and $11,000 as of September 30, 2014 and March 31, 2014, respectively.

The Company reserves for known and potential returns from customers and associated refunds or credits related to such returns based upon historical experience. In certain cases, retailer customers are provided a fixed allowance, usually in the 1% to 2% range, to cover returned goods and this allowance is deducted from payments made to us by such customers. As of September 30, 2014 and March 31, 2014, the Company has recorded a reserve for customer returns of $33,000 and $61,000, respectively.

Recently Issued Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers," which amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2018 using one of two prescribed retrospective methods. Early adoption is not permitted. We have not yet selected a transition method, nor have we determined the effect of the standard on our ongoing financial reporting.

3_Notes_Payable_Long_Term_Debt

3. Notes Payable, Long Term Debt and Current Portion - Long Term Debt	6 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	3. Notes Payable, Long Term Debt and Current Portion – Long Term Debt

	Refer to the Company’s Annual Report on Form 10-K for the year ended March 31, 2014, as filed with the SEC on June 30, 2014 for a detailed discussion on our previously outstanding Notes Payable, Long Term Debt and Current Portion – Long Term Debt. The following are the changes to our Notes Payable, Long Term Debt and Current Portion – Long Term Debt for the periods presented.

	As of September 30, 2014 and March 31, 2014, the outstanding balance of the Company’s notes payable and debt, including accrued interest, is as follows:

		September 30,		March 31,
		2014		2014
		(in thousands)		(in thousands)
	Notes payable	$	2,537	$	-
	Derivative warrant liability (see Note 4)		2,742		2,530
	Sale of intellectual property liability (see Note 4)		232		258
	Total debt		5,511		2,788
	Less notes payable and current portion – long term debt		5,511		2,788
	Long Term Debt	$	-	$	-

	Scotts Miracle-Gro Term Loan

	On July 10, 2014, AeroGrow entered into a Term Loan Agreement in the principal amount of up to $4.5 million with Scotts Miracle-Gro. The proceeds were made available as needed in three advances of up to $1.0 million, $1.5 million, and $2.0 million in July, August, and after September of 2014, respectively, with a due date of February 15, 2015. The funding provided general working capital and was used for the purpose of acquiring inventory to support anticipated growth as the Company expands its retail and its direct-to-consumer sales channels. The Term Loan Agreement is secured by a lien on the assets of the Company. Interest is charged at the stated rate of 10% per annum, but will paid in shares of AeroGrow common stock, valued at a price per share equal to the conversion price of the Series B Convertible Preferred Stock (which was previously issued to Scotts Miracle-Gro in April 2013). The accrued and unpaid interest on the Term Loan is due and payable within thirty (30) days after the Interest Payment Trigger Date (as defined in the Term Loan Agreement). The Term Loan may be prepaid from time to time, in whole or in part, in an amount greater than or equal to $25,000, without penalty or premium. Amounts repaid or prepaid in respect of the Term Loan may not be reborrowed. The Term Loan Agreement has been filed as an exhibit to a Current Report on Form 8-K filed with the SEC on July 16, 2014. As of September 30, 2014, the outstanding balance of the Term Loan, including accrued interest, was $2.5 million and we were current and in compliance with all terms and conditions. See Note 9 for subsequent events.

	Liability Associated with Scotts Miracle-Gro Transaction

	On April 22, 2013, the Company issued Series B Convertible Preferred Stock and a warrant to a wholly-owned subsidiary of Scotts Miracle-Gro. Pursuant to U.S. GAAP, the Company has classified the warrant as a liability at its estimated fair value. The derivative warrant liability will be re-measured to fair value, on a recurring basis, at the end of each reporting period until it is exercised or expires. The valuation techniques used to determine the fair value of the derivative warrant liability and the terms of the warrant are further explained in Note 4. As of September 30, 2014 and March 31, 2014, the estimated fair value of the warrant was $2.7 million and $2.5 million, respectively.

	The Company and Scotts Miracle-Gro also agreed to enter an Intellectual Property Sale Agreement, a Technology License Agreement, a Brand License Agreement, and a Supply Chain Services Agreement. The Intellectual Property Sale Agreement and the Technology License constitute an agreement of sales of future revenues. Since the Company received cash from Scotts Miracle-Gro and agreed to pay for a defined period a specified percentage of revenue, and because the Company has significant involvement in the generation of its revenue, the excess paid over net book value is classified as debt and is being amortized under the effective interest method. As of September 30, 2014 and March 31, 2014, $232,000 and $258,000, respectively, was recorded as a liability on the condensed balance sheets.

4_Scotts_MiracleGro_Transactio

4. Scotts Miracle-Gro Transactions - Convertible Preferred Stock, Warrants and Other Transactions	6 Months Ended
	Sep. 30, 2014
Convertible Preferred Stock Warrants And Other Transactions [Abstract]	'
Convertible Preferred Stock Warrants And Other Transactions [Text Block]	'
	4. Scotts Miracle-Gro Transactions – Convertible Preferred Stock, Warrants and Other Transactions

	Series B Convertible Preferred Stock and Related Transactions

	On April 22, 2013, the Company entered into a Securities Purchase Agreement with Scotts Miracle-Gro. Pursuant to the Securities Purchase Agreement, Scotts Miracle-Gro acquired 2,649,007 shares of the Company’s Series B Convertible Preferred Stock, par value $0.001 per share and (ii) a warrant to purchase shares of the Company’s common stock (the “Warrant,” as described in greater detail below) for an aggregate purchase price of $4.0 million. After deducting offering expenses, including commissions and expenses paid to the Company’s advisor, net cash proceeds totaled to $3.8 million. The Company used $950,000 of the net proceeds to repay “in full” (with concessions) the Promissory Note due to Main Power.

	The Company also issued a warrant to purchase 125,000 shares of the Company’s common stock to the placement agent. This warrant has an exercise price of $1.54 per share (125% of the average closing price of the Company’s common stock during the five-day period prior to the April 22, 2013 closing date). The value of this warrant was estimated at $108,000, based on the Black-Scholes model with a stock price of $1.30, calculated exercise price of $1.54, expected life of three years, annualized volatility of 117.2% and a discount rate of 0.39%. The value of the warrant was recorded as stock issuance costs.

	The Series B Preferred Stock is convertible into 2,649,007 shares of the Company’s common stock ($4.0 million divided by a conversion price of $1.51 per share). The Series B Preferred Stock bears a cumulative annual dividend of 8.0%, payable in shares of the Company’s common stock at a conversion price of $1.51 per share (subject to customary anti-dilution rights, as described in the Series B Preferred Stock Certificates of Designations). The Series B Preferred Stock does not have a liquidation preference and shall vote on an “as-converted” basis with the common stock. The stock dividend will accrue from day to day and will be payable in shares of our common stock within thirty days after the end of each fiscal year end. The stock dividend issuable will be recorded at the fair market value of our common stock at the end of each quarter in the equity section of the balance sheet. The corresponding charge will be recorded below net income to arrive at net income available to common shareholders. The Series B Preferred Stock automatically converts into the Company’s common stock: (i) upon the affirmative election of the holders of at least a majority of the then outstanding shares of the Series B Preferred Stock voting together as a single class on an as-if-converted to common stock basis; or (ii) if, at the date of exercise in whole or in part of the Warrant, the holder (or holders) of the Series B Preferred Stock own 50.1% of the issued and the Company’s then-outstanding common stock, giving effect to the issuance of shares of common stock in connection with the conversion of the Series B Preferred Stock and such exercise of the Warrant.

	The Warrant entitles, but does not obligate, Scotts Miracle-Gro to purchase a number of shares of common stock that, on a “fully diluted basis” (as defined in the Securities Purchase Agreement), constitute 80% of the Company’s outstanding capital stock (when added to all other shares owned by Scotts Miracle-Gro), as calculated as of the date or dates of exercise. The Warrant can be exercised at any time and from time to time for a period of five years between April 22, 2016 and April 22, 2021 (the third and eighth anniversary of the closing date, respectively). In addition, the Warrant can be exercised in any increment; there is no obligation to exercise the entire Warrant at one time. The exercise price of the Warrant shall be equal to the quotient obtained by dividing:

		(a)	an amount equal to (i) 1.34 times the trailing twelve months “Net Sales” (which includes sales of the Company’s products by Scotts Miracle-Gro and its affiliates) minus (ii) “Debt Outstanding” net of cash (as such terms are defined in the Warrant),

	by

		(b)	the total shares of capital stock outstanding, including outstanding in-the-money options and warrants, but not the Warrant contemplated in this Private Offering.

	The Warrant expires on April 22, 2021, the eighth anniversary of the closing date. The Warrant contains customary anti-dilution rights (for stock splits, stock dividends and sales of substantially all the Company’s assets). Scotts Miracle-Gro also has the right to participate pro rata, based on Scotts Miracle-Gro’s percentage equity ownership in the Company (assuming the exercise of Scotts Miracle-Gro’s Warrant, but not the exercise of any options outstanding under the Company’s equity compensation plans) in future issuances of the Company’s equity securities. Upon exercise of the Warrant and demand by Scotts Miracle-Gro, the Company must use its best efforts to file a Registration Statement on Form S-3, or, if the Company is not eligible for Form S-3, on Form S-1 (collectively, the “Registration Statement”), covering the shares of the Company’s common stock covered by the Preferred Stock and the Warrant, within 120 calendar days after receipt of Scotts Miracle-Gro’s demand for registration and shall use its best efforts to cause the Registration Statement to become effective as soon as possible thereafter.

	The private offering and sale of the Series B Preferred Stock and Warrant was conducted in reliance upon exemptions from registration requirements under the Securities Act, including, without limitation, those under Regulation D promulgated under the Securities Act. Scotts Miracle-Gro is an “accredited investor,” as defined in Rule 501 of Regulation D under the Securities Act. Because the Series B Preferred Stock and the Warrant have not been registered under the Securities Act, they may not be reoffered or resold in the United States absent registration or an applicable exemption from registration.

	The foregoing description of the Securities Purchase Agreement, the Certificates of Designations for the Series B Convertible Preferred Stock, the Warrant, and the resulting transaction is only a summary, does not purport to be complete, and is qualified in its entirety by reference to the full text of the applicable documents, each of which was included as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on April 23, 2013. The warrant on the Series B Convertible Preferred Stock was accounted for as a liability at its estimated fair value of $2.7 million as of September 30, 2014. The derivative warrant liability will be re-measured to fair value, on a recurring basis, at the end of each reporting period it is exercised or expires. The Company calculated the fair value of the Warrant during the quarter ended September 30, 2014 using a Monte Carlo simulation model.

	In conjunction with the private offering of Series B Preferred Stock and the Warrant above, the Company used $950,000 of the net proceeds to repay “in full” (with concessions) a Promissory Note with Main Power, one of the Company’s principal suppliers. Main Power also released the Company’s pledged collateral and the parties agreed to terminate the Letter Agreement and Promissory Note effective as of April 22, 2013, as further described in Note 3 of the Form 10-K for the year ended March 31, 2014, as filed with the SEC on June 30, 2014. The Company did not incur any early termination penalties. As of April 23, 2013, there was $237,000 in consignment inventory held by Main Power that was fully reserved for during the three month period ended June 30, 2013.

	In conjunction with the private offering described above, the Company and Scotts Miracle-Gro also agreed to enter an Intellectual Property Sale Agreement, a Technology License Agreement, a Brand License Agreement, and a Supply Chain Services Agreement. The Intellectual Property Sale Agreement and the Technology License constitute an agreement of sales of future revenues. For more details regarding these agreements, please refer to Note 3 “Scotts Miracle-Gro Transactions” to the financial statements included in the Company’s Annual Report on Form 10-K, as filed with the SEC on June 30, 2014. See also Note 3 for the Term Loan with Scotts Miracle-Gro.

5_Equity_Compensation_Plans

5. Equity Compensation Plans	6 Months Ended
5. Equity Compensation Plans	Sep. 30, 2014
Share-based Arrangements with Employees and Nonemployees [Abstract]	'
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	'
	5. Equity Compensation Plans

	For the three and six months ended September 30, 2014, the Company granted 93,000 options to purchase the Company’s common stock under the Company’s 2005 Equity Compensation Plan (the “2005 Plan”). For the three and six months ended September 30, 2013, the Company granted 150,000 options to purchase the Company’s common stock under the 2005 Plan.

	During the three and six months ended September 30, 2014, options to purchase 2,000 shares of common stock were cancelled or expired. During the three months ended September 30 2014, 16,000 shares and during the six months end September 30, 2014, 17,000 shares of common stock were issued upon exercise of outstanding stock options under the 2005 Plan. During the three and six months ended September 30, 2013, options to purchase 32,000 shares of common stock were cancelled or expired, and no shares of common stock were issued upon exercise of outstanding stock options under the 2005 Plan.

	As of September 30, 2014, unvested options to purchase an aggregate of 203,000 shares of the Company’s common stock were outstanding. The Company will incur up to $387,000 of compensation expense in future periods if these options fully vest.

	Information regarding all stock options outstanding under the 2005 Plan as of September 30, 2014 is as follows:

			OPTIONS OUTSTANDING								OPTIONS EXERCISABLE
	Exercise		Options		Weighted-average		Weighted-average		Aggregate		Options	Weighted-average		Weighted- average		Aggregate
	price range		(in thousands)		Remaining		Exercise Price		Intrinsic Value		(in thousands)	Remaining		Exercise Price		Intrinsic Value
					Contractual				(in thousands)			Contractual				(in thousands)
					Life (years)							Life (years)
	$	1.01		106		3.36	$	1.01			72		3.36	$	1.01
	$	1.1		50		3.5	$	1.1			50		3.5	$	1.1
	$	1.21		50		3.5	$	1.21			50		3.5	$	1.21
	$	2.2		162		3.94	$	2.2			82		3.87	$	2.2
	$	2.42		10		4.02	$	2.42			9		4.02	$	2.42
	$	5.31		93		4.85	$	5.31			5		4.85	$	5.31
				471		3.9	$	2.33	$	984	268		3.62	$	1.55	$	716

	The aggregate intrinsic value in the preceding table represents the difference between the Company’s closing stock price and the exercise price of each in-the-money option on the last trading day of the period presented, which was September 30, 2014.

6_Income_Taxes

6. Income Taxes	6 Months Ended
6. Income Taxes	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	6. Income Taxes

	The Company follows the guidance in ASC 740, Accounting for Uncertainty in Income Taxes (“ASC 740”) which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. This interpretation defines the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements.

	Deferred income taxes are recognized for the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at the end of each period, based on enacted laws and statutory rates applicable to the periods in which the differences are expected to affect taxable income. Any liability for actual taxes to taxing authorities is recorded as income tax liability. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established against such assets where management is unable to conclude more likely than not that such asset will be realized. As of September 30, 2014 and March 31, 2014, the Company recognized a valuation allowance equal to 100% of the net deferred tax asset balance and the Company has no unrecognized tax benefits related to uncertain tax positions.

7_Related_Party_Transactions

7. Related Party Transactions	6 Months Ended
7. Related Party Transactions	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	7. Related Party Transactions

	See above Note 3 Notes Payable, Long Term Debt and Current Portion – Long Term Debt for disclosure of related party transactions. See Note 3 of our Form 10-K for the year ended March 31, 2014, as filed with the SEC on June 30, 2014 for a detailed discussion of any related party transactions during the prior year period.

8_Stockholders_Equity

8. Stockholders' Equity	6 Months Ended
8. Stockholders' Equity	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	8. Stockholders’ Equity

	A summary of the Company’s common stock warrant activity for the period from April 1, 2014 through September 30, 2014 is presented below:

			Warrants Outstanding				Weighted Average				Aggregate Intrinsic Value
			(in thousands)				Exercise Price				(in thousands)
	Outstanding, April 1, 2014			575			$	20.24			$	383
	Granted			-				-
	Exercised			-				-
	Expired			(8	)			802.09
	Outstanding, September 30, 2014			567			$	9.39			$	105

	As of September 30, 2014, the Company had the following outstanding warrants to purchase its common stock:

					Weighted Average
	Warrants Outstanding (in thousands)				Exercise Price				Remaining Life (Years)
		50			$	2.1				4.02
		394			$	7				2.53
		122			$	20				0.62
		1			$	25				0.08
		567			$	9.39				2.25

	As discussed in Note 4, the Company also issued a warrant that entitles, but does not obligate Scotts Miracle-Gro to purchase a number of shares of common stock that, on a fully diluted basis, constitute 80% of the Company’s outstanding capital stock. The warrant on the Series B Convertible Preferred Stock was accounted for as a liability at its estimated fair value. The warrant liability will be re-measured to fair value at the end of each reporting period until it is exercised or expires. The tables above exclude the warrant issued to Scotts Miracle-Gro because the number of shares issuable upon exercise of the warrant is not determinable, as discussed above.

9_Subsequent_Events

9. Subsequent Events	6 Months Ended
9. Subsequent Events	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	9. Subsequent Events

	On October 14, 2014, the Company exercised the final draw of $2.0 million on the Term Loan Agreement entered into on July 10, 2014, in the principal amount of up to $4.5 million, with Scotts Miracle-Gro. The proceeds were made available as needed in three advances of up to $1.0 million, $1.5 million, and $2.0 million in July, August, and September of 2014, respectively, with a due date of February 15, 2015. The Term Loan Agreement is secured by a lien on the assets of the Company. Interest is charged at the stated rate of 10% per annum, but will paid in shares of AeroGrow common stock, valued at a price per share equal to the conversion price of the Series B Preferred Conversion Price on the date the Term Loan. The funding provided general working capital and was used for the purpose of acquiring inventory to support anticipated growth as the Company expands its retail and its direct-to-consumer sales channels. The first advance on $1.0 million was borrowed in July 2014, followed by an additional $1.5 million and $2.0 million in August and October 2014, respectively.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	6 Months Ended
Accounting Policies, by Policy (Policies)	Sep. 30, 2014
Accounting Policies [Abstract]	'
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates

	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. It is reasonably possible that a change in the Company’s estimates could occur in the near term as information becomes available.
Reclassification, Policy [Policy Text Block]	'
	Reclassifications

	Certain prior year amounts have been reclassified to conform to current year presentation.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	'
	Accounts Receivable and Allowance for Doubtful Accounts

	The Company sells its products to retailers and consumers. Consumer transactions are primarily paid by credit card. Retailer sales terms vary by customer, but generally range from net 30 days to net 60 days. Accounts receivable are reported at net realizable value and net of the allowance for doubtful accounts. The Company uses the allowance method to account for uncollectible accounts receivable. The Company's allowance estimate is based on a review of the current status of trade accounts receivable, which resulted in an allowance of $9,000 and $5,000 at September 30, 2014 and March 31, 2014, respectively.

	Other Receivables

	In conjunction with the Company’s processing of credit card transactions for its direct-to-consumer sales activities and as security with respect to the Company’s performance for credit card refunds and charge backs, the Company is required to maintain a cash reserve with Litle and Company, the Company’s credit card processor. This reserve is equal to 5% of the credit card sales processed during the previous six months. As of September 30, 2014 and March 31, 2014, the balance in this reserve account was $81,000 and $187,000, respectively.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition

	The Company recognizes revenue from product sales, net of estimated returns, when persuasive evidence of a sale exists, including the following; (i) a product is shipped under an agreement with a customer; (ii) the risk of loss and title has passed to the customer; (iii) the fee is fixed or determinable; and (iv) collection of the resulting receivable is reasonably assured.

	The Company records estimated reductions to revenue for customer and distributor programs and incentive offerings, including promotions, rebates, and other volume-based incentives. Certain incentive programs require the Company to estimate based on industry experience the number of customers who will actually redeem the incentive. As of September 30, 2014 and March 31, 2014, the Company had accrued $39,000 and $42,000, respectively, as its estimate for the foregoing deductions and allowances.
Standard Product Warranty, Policy [Policy Text Block]	'
	Warranty and Return Reserves

	The Company records warranty liabilities at the time of sale for the estimated costs that may be incurred under its basic warranty program. The specific warranty terms and conditions vary depending upon the product sold but generally include technical support, repair parts, and labor for periods up to one year. Factors that affect the Company’s warranty liability include the number of installed units currently under warranty, historical and anticipated rates of warranty claims on those units, and cost per claim to satisfy the Company’s warranty obligation. Based upon the foregoing, the Company has recorded a provision for potential future warranty costs of $17,000 and $11,000 as of September 30, 2014 and March 31, 2014, respectively.

	The Company reserves for known and potential returns from customers and associated refunds or credits related to such returns based upon historical experience. In certain cases, retailer customers are provided a fixed allowance, usually in the 1% to 2% range, to cover returned goods and this allowance is deducted from payments made to us by such customers. As of September 30, 2014 and March 31, 2014, the Company has recorded a reserve for customer returns of $33,000 and $61,000, respectively.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Issued Accounting Pronouncements

	In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers," which amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2018 using one of two prescribed retrospective methods. Early adoption is not permitted. We have not yet selected a transition method, nor have we determined the effect of the standard on our ongoing financial reporting.

2_Liquidity_and_Basis_of_Prese1

2. Liquidity and Basis of Presentation (Tables)	6 Months Ended
2. Liquidity and Basis of Presentation (Tables)	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'The Company calculated the fair value of the warrant during the quarter ended September 30, 2014 using a Monte Carlo simulation model.

		30-Sep-14				31-Mar-14
		(in thousands)				(in thousands)
		Fair Value		Carry Value		Fair Value		Carry Value
	Liabilities
	Notes payable	$	2,469	$	2,537	$	-	$	-
	Derivative warrant liability		2,742		2,742		2,530		2,530
	Sale of intellectual property liability		158		232		171		258
	Total	$	5,369	$	5,511	$	2,701	$	2,788
Schedule of Advertising Expenses [Table Text Block]	'Advertising expense for the three and six months ended September 30, 2014 and 2013 were as follows:

		Three Months Ended				Six Months Ended
		September 30,				September 30,
		(in thousands)				(in thousands)
		2014		2013		2014		2013
	Direct-to-consumer	$	63	$	40	$	168	$	112
	Retail		5		2		13		2
	Other		-		1		18		4
	Total advertising expense	$	68	$	43	$	199	$	118
Schedule of Inventory, Current [Table Text Block]	'Inventories are valued at the lower of cost, determined by the first-in, first-out method, or market. Included in inventory costs where the Company is the manufacturer are raw materials, labor, and manufacturing overhead. The Company records the raw materials at delivered cost. Standard labor and manufacturing overhead costs are applied to the finished goods based on normal production capacity as prescribed under ASC 330 Inventory Pricing. A majority of the Company’s products are manufactured overseas and are recorded at landed cost which includes product costs for purchased and manufactured products, and freight and transportation costs for inbound freight from manufacturers.

		September 30,		March 31,
		2014		2014
		(in thousands)		(in thousands)
	Finished goods	$	3,954	$	784
	Raw materials		1,063		527
		$	5,017	$	1,311

3_Notes_Payable_Long_Term_Debt1

3. Notes Payable, Long Term Debt and Current Portion - Long Term Debt (Tables)	6 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'As of September 30, 2014 and March 31, 2014, the outstanding balance of the Company’s notes payable and debt, including accrued interest, is as follows:

		September 30,		March 31,
		2014		2014
		(in thousands)		(in thousands)
	Notes payable	$	2,537	$	-
	Derivative warrant liability (see Note 4)		2,742		2,530
	Sale of intellectual property liability (see Note 4)		232		258
	Total debt		5,511		2,788
	Less notes payable and current portion – long term debt		5,511		2,788
	Long Term Debt	$	-	$	-

5_Equity_Compensation_Plans_Ta

5. Equity Compensation Plans (Tables)	6 Months Ended
5. Equity Compensation Plans (Tables)	Sep. 30, 2014
Share-based Arrangements with Employees and Nonemployees [Abstract]	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]	'Information regarding all stock options outstanding under the 2005 Plan as of September 30, 2014 is as follows:

			OPTIONS OUTSTANDING								OPTIONS EXERCISABLE
	Exercise		Options		Weighted-average		Weighted-average		Aggregate		Options	Weighted-average		Weighted- average		Aggregate
	price range		(in thousands)		Remaining		Exercise Price		Intrinsic Value		(in thousands)	Remaining		Exercise Price		Intrinsic Value
					Contractual				(in thousands)			Contractual				(in thousands)
					Life (years)							Life (years)
	$	1.01		106		3.36	$	1.01			72		3.36	$	1.01
	$	1.1		50		3.5	$	1.1			50		3.5	$	1.1
	$	1.21		50		3.5	$	1.21			50		3.5	$	1.21
	$	2.2		162		3.94	$	2.2			82		3.87	$	2.2
	$	2.42		10		4.02	$	2.42			9		4.02	$	2.42
	$	5.31		93		4.85	$	5.31			5		4.85	$	5.31
				471		3.9	$	2.33	$	984	268		3.62	$	1.55	$	716

8_Stockholders_Equity_Tables

8. Stockholders' Equity (Tables)	6 Months Ended
8. Stockholders' Equity (Tables)	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'A summary of the Company’s common stock warrant activity for the period from April 1, 2014 through September 30, 2014 is presented below:

			Warrants Outstanding				Weighted Average				Aggregate Intrinsic Value
			(in thousands)				Exercise Price				(in thousands)
	Outstanding, April 1, 2014			575			$	20.24			$	383
	Granted			-				-
	Exercised			-				-
	Expired			(8	)			802.09
	Outstanding, September 30, 2014			567			$	9.39			$	105
Schedule of Stockholders Equity [Table Text Block]	'As of September 30, 2014, the Company had the following outstanding warrants to purchase its common stock:

					Weighted Average
	Warrants Outstanding (in thousands)				Exercise Price				Remaining Life (Years)
		50			$	2.1				4.02
		394			$	7				2.53
		122			$	20				0.62
		1			$	25				0.08
		567			$	9.39				2.25

2_Liquidity_and_Basis_of_Prese2

2. Liquidity and Basis of Presentation (Details) (USD $)

6 Months Ended

12 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

Sep. 30, 2014

Mar. 31, 2014

Mar. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Oct. 14, 2014

Jul. 10, 2014

Aug. 31, 2014

Jul. 31, 2014

Jul. 30, 2014

Jul. 10, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Mar. 31, 2014

Apr. 22, 2013

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2013

Sep. 30, 2014

Major Supplier 1 [Member]

Major Supplier 2 [Member]

Major Supplier 3 [Member]

Major Supplier 4 [Member]

Major Supplier 5 [Member]

Major Supplier 6 [Member]

Affiliated Entity [Member]

Major Customer 1 [Member]

Major Customer 2 [Member]

Major Customer 3 [Member]

Scotts Miracle-Gro Company [Member]

Allowance for Sales Returns [Member]

Sales Revenue, Net [Member]

Maximum [Member]

Minimum [Member]

Cost of Goods, Total [Member]

Notes Payable, Other Payables [Member]

Sales Revenue, Net [Member]

Accounts Receivable [Member]

Sales Revenue, Net [Member]

Accounts Receivable [Member]

Maximum [Member]

Customer Concentration Risk [Member]

Supplier Concentration Risk [Member]

Subsequent Event [Member]

Customer Concentration Risk [Member]

Credit Concentration Risk [Member]

Customer Concentration Risk [Member]

Credit Concentration Risk [Member]

2. Liquidity and Basis of Presentation (Details) [Line Items]

Revenue, Percentage

60.90%

Debt Instrument, Face Amount

$2,000,000

$1,500,000

$1,000,000

$4,500,000

Debt Instrument, Maturity Date

15-Feb-15

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Proceeds from Notes Payable

2,000,000

1,500,000

1,000,000

Cash, FDIC Insured Amount

250,000

Concentration Risk, Percentage

218.70%

125.80%

127.10%

47.80%

90.60%

50.00%

47.10%

25.70%

50.70%

16.70%

24.70%

8.30%

34.40%

11.30%

17.50%

5.90%

13.60%

14.50%

10.70%

30.40%

27.00%

16.40%

56.90%

44.10%

18.40%

11.60%

15.30%

22.70%

24.50%

11.10%

18.00%

Cost of Goods Sold

2,400,000

489,000

2,800,000

530,000

982,000

194,000

1,000,000

285,000

549,000

65,000

549,000

93,000

373,000

44,000

390,000

65,000

147,000

322,000

116,000

Fair Value Inputs, Discount Rate

15.00%

Equity Method Investment, Ownership Percentage

80.00%

Allowance for Doubtful Accounts Receivable, Current

9,000

5,000

Other receivable, reserve percentage of credit card sales

5.00%

Other Receivables, Net, Current

81,000

187,000

Deferred Advertising Costs

8,000

16,000

Inventory Valuation Reserves

332,000

Other Accrued Liabilities

39,000

42,000

Provision for Future Warranty Costs

17,000

11,000

Returns Reserves Allowance, Percentage

2.00%

1.00%

Customer Refund Liability, Current

$33,000

$61,000

2_Liquidity_and_Basis_of_Prese3

2. Liquidity and Basis of Presentation (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
Liabilities	'	'
Derivative warrant liability	$2,742	$2,530
Sale of intellectual property liability	-2	-2
Total	5,511	2,788
Estimate of Fair Value Measurement [Member]	'	'
Liabilities	'	'
Notes payable	2,469	0
Derivative warrant liability	2,742	2,530
Sale of intellectual property liability	158	171
Total	5,369	2,701
Reported Value Measurement [Member]	'	'
Liabilities	'	'
Notes payable	2,537	0
Derivative warrant liability	2,742	2,530
Sale of intellectual property liability	232	258
Total	$5,511	$2,788

2_Liquidity_and_Basis_of_Prese4

2. Liquidity and Basis of Presentation (Details) - Schedule of Advertising Expenses (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
2. Liquidity and Basis of Presentation (Details) - Schedule of Advertising Expenses [Line Items]	'	'	'	'
Advertising expense	$68	$43	$199	$118
Direct-to-consumer [Member]	'	'	'	'
2. Liquidity and Basis of Presentation (Details) - Schedule of Advertising Expenses [Line Items]	'	'	'	'
Advertising expense	63	40	168	112
Retail [Member]	'	'	'	'
2. Liquidity and Basis of Presentation (Details) - Schedule of Advertising Expenses [Line Items]	'	'	'	'
Advertising expense	5	2	13	2
Other Advertising [Member]	'	'	'	'
2. Liquidity and Basis of Presentation (Details) - Schedule of Advertising Expenses [Line Items]	'	'	'	'
Advertising expense	$0	$1	$18	$4

2_Liquidity_and_Basis_of_Prese5

2. Liquidity and Basis of Presentation (Details) - Schedule of Inventory (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
Schedule of Inventory [Abstract]	'	'
Finished goods	$3,954	$784
Raw materials	1,063	527
	$5,017	$1,311

3_Notes_Payable_Long_Term_Debt2

3. Notes Payable, Long Term Debt and Current Portion - Long Term Debt (Details) (USD $)	Sep. 30, 2014	Mar. 31, 2014	Oct. 14, 2014	Jul. 10, 2014	Aug. 31, 2014	Jul. 31, 2014	Jul. 30, 2014	Jul. 10, 2014
			Affiliated Entity [Member]	Affiliated Entity [Member]	Affiliated Entity [Member]	Affiliated Entity [Member]	Affiliated Entity [Member]	Affiliated Entity [Member]
			Notes Payable, Other Payables [Member]	Notes Payable, Other Payables [Member]	Notes Payable, Other Payables [Member]	Notes Payable, Other Payables [Member]	Notes Payable, Other Payables [Member]	Notes Payable, Other Payables [Member]
			Subsequent Event [Member]
3. Notes Payable, Long Term Debt and Current Portion - Long Term Debt (Details) [Line Items]	'	'	'	'	'	'	'	'
Debt Instrument, Face Amount	'	'	$2,000,000	'	$1,500,000	$1,000,000	$1,000,000	$4,500,000
Debt Instrument, Maturity Date	'	'	'	15-Feb-15	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	'	'	'	'	'	'	'	10.00%
Debt Instrument, Payment Terms	'	'	'	'thirty (30) days after the Interest Payment Trigger Date	'	'	'	'
Debt Instrument, Periodic Payment	'	'	'	25,000	'	'	'	'
Notes Payable, Current	2,537,000	0	'	'	'	'	'	'
Derivative Liability, Current	2,742,000	2,530,000	'	'	'	'	'	'
Debt, Current	$232,000	$258,000	'	'	'	'	'	'

3_Notes_Payable_Long_Term_Debt3

3. Notes Payable, Long Term Debt and Current Portion - Long Term Debt (Details) - Schedule of Debt (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
Schedule of Debt [Abstract]	'	'
Notes payable	$2,537	$0
Derivative warrant liability (see Note 4)	2,742	2,530
Sale of intellectual property liability (see Note 4)	232	258
Total debt	5,511	2,788
Less notes payable and current portion b long term debt	5,511	2,788
Long Term Debt	$0	$0

4_Scotts_MiracleGro_Transactio1

4. Scotts Miracle-Gro Transactions - Convertible Preferred Stock, Warrants and Other Transactions (Details) (USD $)	6 Months Ended	12 Months Ended		0 Months Ended			0 Months Ended
	Sep. 30, 2014	Mar. 31, 2014	Apr. 23, 2013	Apr. 22, 2013	Apr. 22, 2013	Apr. 22, 2013	Apr. 22, 2013	Apr. 22, 2013
				Series B Preferred Stock [Member]	Scotts Miracle-Gro Company [Member]	Scotts Miracle-Gro Company [Member]	Main Power Promissory Note [Member]	Main Power Promissory Note [Member]
				Scotts Miracle-Gro Company [Member]	Private Placement Agent [Member]	Maximum [Member]
4. Scotts Miracle-Gro Transactions - Convertible Preferred Stock, Warrants and Other Transactions (Details) [Line Items]	'	'	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues (in Shares)	'	'	'	2,649,007	'	'	'	'
Shares Issued, Price Per Share (in Dollars per share)	'	'	'	$0.00	'	'	'	'
Stock Issued During Period, Value, New Issues	'	'	'	$4,000,000	'	'	'	'
Proceeds from Issuance of Convertible Preferred Stock	'	'	'	3,800,000	'	'	'	'
Repayments of Debt	'	'	'	'	'	'	950,000	950,000
Class of Warrant or Rights, Granted (in Shares)	0	'	'	'	125,000	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	'	'	'	'	$1.54	'	'	'
Class of Warrant or Rights, Exercise Price, Description	'	'	'	'	'125% of the average closing price of the Company’s common stock during the five-day period prior to the April 22, 2013 closing date	'	'	'
Fair Value Adjustment of Warrants	'	'	'	'	108,000	'	'	'
Share Price (in Dollars per share)	'	'	'	'	$1.30	'	'	'
Fair Value Assumptions, Expected Term	'	'	'	'	'3 years	'	'	'
Fair Value Assumptions, Expected Volatility Rate	'	'	'	'	117.20%	'	'	'
Fair Value Inputs, Discount Rate	15.00%	15.00%	'	'	0.39%	'	'	'
Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)	'	'	'	2,649,007	'	'	'	'
Preferred Stock, Conversion Basis	'	'	'	'$4.0 million divided by a conversion price of $1.51 per share	'	'	'	'
Preferred Stock, Dividend Rate, Percentage	'	'	'	8.00%	'	'	'	'
Preferred Stock, Dividend Rate, Per-Dollar-Amount (in Dollars per share)	'	'	'	$1.51	'	'	'	'
Registration Payment Arrangement, Term	'	'	'	'thirty days after the end of each fiscal year end	'	'	'	'
Convertible Preferred Stock, Terms of Conversion	'	'	'	'(i) upon the affirmative election of the holders of at least a majority of the then outstanding shares of the Series B Preferred Stock voting together as a single class on an as-if-converted to common stock basis; or (ii) if, at the date of exercise in whole or in part of the Warrant, the holder (or holders) of the Series B Preferred Stock own 50.1% of the issued and the Company’s then-outstanding common stock, giving effect to the issuance of shares of common stock in connection with the conversion of the Series B Preferred Stock and such exercise of the Warrant.	'	'	'	'
Equity Method Investment, Ownership Percentage	'	'	'	'	'	80.00%	'	'
Class of Warrant or Rights, Term of Warrant or Rights	'	'	'	'5 years	'	'	'	'
Derivative Liability, Current	2,742,000	2,530,000	'	'	'	'	'	'
Inventory Held on Consignment	'	'	$237,000	'	'	'	'	'

5_Equity_Compensation_Plans_De

5. Equity Compensation Plans (Details) (USD $)	3 Months Ended		6 Months Ended
5. Equity Compensation Plans (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
5. Equity Compensation Plans (Details) [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	93,000	'	93,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	'	'	'	32,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	'	0	'	0
Equity Compensation Plan (2005 Plan) [Member]	'	'	'	'
5. Equity Compensation Plans (Details) [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	150,000	'	150,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	2,000	'	2,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	16,000	32,000	17,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares	203,000	'	203,000	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)	387,000	'	387,000	'

5_Equity_Compensation_Plans_De1

5. Equity Compensation Plans (Details) - Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable (Equity Compensation Plan (2005 Plan) [Member], USD $)	6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014
5. Equity Compensation Plans (Details) - Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Line Items]	'
Options Outstanding (in Shares)	471
Options Outstanding, Weighted-average Remaining Contractual Life	'3 years 328 days
Options Outstanding, Weighted-average Exercise Price	$2.33
Options Outstanding, Aggregate Intrinsic Value (in Dollars)	$984
Options Exercisable (in Shares)	268
Options Exercisable, Weighted-average Remaining Contractual Life	'3 years 226 days
Options Exercisable, Weighted-average Exercise Price	$1.55
Options Exercisable, Aggregate Intrinsic Value (in Dollars)	$716
Options Exercise Price $1.01 [Member]	'
5. Equity Compensation Plans (Details) - Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Line Items]	'
Exercise Price	$1.01
Options Outstanding (in Shares)	106
Options Outstanding, Weighted-average Remaining Contractual Life	'3 years 131 days
Options Outstanding, Weighted-average Exercise Price	$1.01
Options Exercisable (in Shares)	72
Options Exercisable, Weighted-average Remaining Contractual Life	'3 years 131 days
Options Exercisable, Weighted-average Exercise Price	$1.01
Options Exercise Price $1.10 [Member]	'
5. Equity Compensation Plans (Details) - Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Line Items]	'
Exercise Price	$1.10
Options Outstanding (in Shares)	50
Options Outstanding, Weighted-average Remaining Contractual Life	'3 years 6 months
Options Outstanding, Weighted-average Exercise Price	$1.10
Options Exercisable (in Shares)	50
Options Exercisable, Weighted-average Remaining Contractual Life	'3 years 6 months
Options Exercisable, Weighted-average Exercise Price	$1.10
Options Exercise Price $1.21 [Member]	'
5. Equity Compensation Plans (Details) - Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Line Items]	'
Exercise Price	$1.21
Options Outstanding (in Shares)	50
Options Outstanding, Weighted-average Remaining Contractual Life	'3 years 6 months
Options Outstanding, Weighted-average Exercise Price	$1.21
Options Exercisable (in Shares)	50
Options Exercisable, Weighted-average Remaining Contractual Life	'3 years 6 months
Options Exercisable, Weighted-average Exercise Price	$1.21
Options Exercise Price $2.20 [Member]	'
5. Equity Compensation Plans (Details) - Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Line Items]	'
Exercise Price	$2.20
Options Outstanding (in Shares)	162
Options Outstanding, Weighted-average Remaining Contractual Life	'3 years 343 days
Options Outstanding, Weighted-average Exercise Price	$2.20
Options Exercisable (in Shares)	82
Options Exercisable, Weighted-average Remaining Contractual Life	'3 years 317 days
Options Exercisable, Weighted-average Exercise Price	$2.20
Options Exercise Price $2.42 [Member]	'
5. Equity Compensation Plans (Details) - Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Line Items]	'
Exercise Price	$2.42
Options Outstanding (in Shares)	10
Options Outstanding, Weighted-average Remaining Contractual Life	'4 years 7 days
Options Outstanding, Weighted-average Exercise Price	$2.42
Options Exercisable (in Shares)	9
Options Exercisable, Weighted-average Remaining Contractual Life	'4 years 7 days
Options Exercisable, Weighted-average Exercise Price	$2.42
Options Exercise Price $5.31 [Member]	'
5. Equity Compensation Plans (Details) - Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Line Items]	'
Exercise Price	$5.31
Options Outstanding (in Shares)	93
Options Outstanding, Weighted-average Remaining Contractual Life	'4 years 310 days
Options Outstanding, Weighted-average Exercise Price	$5.31
Options Exercisable (in Shares)	5
Options Exercisable, Weighted-average Remaining Contractual Life	'4 years 310 days
Options Exercisable, Weighted-average Exercise Price	$5.31

6_Income_Taxes_Details

6. Income Taxes (Details) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'	'
Unrecognized Tax Benefits	$0	$0

8_Stockholders_Equity_Details

8. Stockholders' Equity (Details) (Scotts Miracle-Gro Company [Member], Maximum [Member])	Apr. 22, 2013
Scotts Miracle-Gro Company [Member] \| Maximum [Member]	'
8. Stockholders' Equity (Details) [Line Items]	'
Equity Method Investment, Ownership Percentage	80.00%

8_Stockholders_Equity_Details_

8. Stockholders' Equity (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights (USD $)	6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]	'
Warrants Outstanding	575
Warrants Outstanding, Weighted Average Exercise Price	$20.24
Warrants Outstanding, Aggregate Intrinsic Value	$383
Granted	0
Granted	$0
Exercised	0
Exercised	$0
Expired	-8
Expired	$802.09
Warrants Outstanding	567
Warrants Outstanding, Weighted Average Exercise Price	$9.39
Warrants Outstanding, Aggregate Intrinsic Value	$105

8_Stockholders_Equity_Details_1

8. Stockholders' Equity (Details) - Schedule of Warrants Outstanding (USD $)	6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
8. Stockholders' Equity (Details) - Schedule of Warrants Outstanding [Line Items]	'	'
Warrants Outstanding	567	575
Weighted Average Exercise Price	$9.39	$20.24
Weighted Average Remaing Life (Yrs)	'2 years 3 months	'
Warrants Exercisable at $2.10 [Member]	'	'
8. Stockholders' Equity (Details) - Schedule of Warrants Outstanding [Line Items]	'	'
Warrants Outstanding	50	'
Weighted Average Exercise Price	$2.10	'
Weighted Average Remaing Life (Yrs)	'4 years 7 days	'
Warrants Exercisable at $7.00 [Member]	'	'
8. Stockholders' Equity (Details) - Schedule of Warrants Outstanding [Line Items]	'	'
Warrants Outstanding	394	'
Weighted Average Exercise Price	$7	'
Weighted Average Remaing Life (Yrs)	'2 years 193 days	'
Warrants exercisable at $20.00 [Member]	'	'
8. Stockholders' Equity (Details) - Schedule of Warrants Outstanding [Line Items]	'	'
Warrants Outstanding	122	'
Weighted Average Exercise Price	$20	'
Weighted Average Remaing Life (Yrs)	'226 days	'
Warrants Exercisable at $25.00 [Member]	'	'
8. Stockholders' Equity (Details) - Schedule of Warrants Outstanding [Line Items]	'	'
Warrants Outstanding	1	'
Weighted Average Exercise Price	$25	'
Weighted Average Remaing Life (Yrs)	'29 days	'

9_Subsequent_Events_Details

9. Subsequent Events (Details) (Affiliated Entity [Member], Notes Payable, Other Payables [Member], USD $)	0 Months Ended		0 Months Ended	1 Months Ended
In Millions, unless otherwise specified	Oct. 14, 2014	Oct. 14, 2014	Jul. 10, 2014	Aug. 31, 2014	Jul. 31, 2014	Jul. 30, 2014	Jul. 10, 2014
	Subsequent Event [Member]	Subsequent Event [Member]	Jul. 10, 2014	Aug. 31, 2014	Jul. 31, 2014	Jul. 30, 2014	Jul. 10, 2014
9. Subsequent Events (Details) [Line Items]	'	'	'	'	'	'	'
Debt Instrument, Face Amount	'	$2	'	$1.50	$1	$1	$4.50
Debt Instrument, Maturity Date	'	'	15-Feb-15	'	'	'	'
Debt Instrument, Collateral	'	'	'secured by a lien on the assets of the Company	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	'	'	'	'	'	'	10.00%
Proceeds from Notes Payable	$2	'	'	$1.50	$1	'	'